Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: A randomized, open-label, single-dose, two-way crossover study in adult smokers

Clinical Therapeutics

Volumn 32, Issue 6, 2010, Pages 1140-1148

  DeVeaugh Geiss, Angela M ^a   Chen, Lilan H ^a   Kotler, Mitchell L ^a   Ramsay, Lisa R ^a   Durcan, Michael J ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Nicorette Invisi patch; Nicotine; Nicotine patch; Nicotine transdermal systems; NiQuitin; Pharmacokinetics

Indexed keywords

NICABATE; NICORETTE INVISI PATCH; NICOTINE; NICOTINE PATCH; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PAPULE; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMOKING CESSATION; TIME TO MAXIMUM PLASMA CONCENTRATION; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; SMOKING;

EID: 77954638974     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.06.008     Document Type: Article

References (26)

1. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008, (1):CD000146.
2. Gore AV, Chien YW The nicotine transdermal system. Clin Dermatol 1998, 16:599-615.
3. Benowitz NL Clinical pharmacology of transdermal nicotine. Eur J Pharm Biopharm 1995, 41:168-174.
4. Fagerström KO, Säwe U, Tønnesen P Therapeutic use of nicotine patches: Efficacy and safety. J Smoking Related Disord 1992, 3:247-261.
5. Gorsline J Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 1993, 17:20-24.
6. Henningfield JE Nicotine medications for smoking cessation. N Engl J Med. 1995, 333:1196-1203.
7. Palmer KJ, Buckley MM, Faulds D Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992, 44:498-529.
8. Fant RV, Henningfield JE, Shiffman S, et al. A pharma-cokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav. 2000, 67:479-482.
9. Summary of product characteristics. Nicorette Invisi 25 mg patch Electronic Medicines Compendium, Accessed December 17, 2009. http://www.medicines.org.uk/EMC/medicine/21381/SPC/Nicorette+invisi+25+mg+patch./.
10. Birgersson J, Hansson A, Molander L, et al. Pharmacokinetics of a new nicotine 16H transdermal patch. Proceedings of the 2008 European Society for Research on Nicotine and Tobacco Accessed December 17, 2009. http://www.srnt.org/meeting/eu/08_europe.html.
11. Summary of product characteristics. NiQuitin 21 mg transdermal patches Electronic Medicines Compendium, Accessed December 17, 2009. http://www.medicines.org.uk/emc/printfriendlydocument.aspx?documentid=15340&companyid=890.
12. Benowitz NL, Jacob P, Jones RT, Rosenberg J Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther. 1982, 221:368-372.
13. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects Accessed March 17, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
14. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Accessed March 17, 2010. http://www.ich.org/LOB/media/MEDIA482.pdf.
15. Title 21, Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies CFR-Code of Federal Regulations, Accessed April 28, 2010. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58.
16. Guidance for Industry. Bioanalytical method validation US Food and Drug Administration, Accessed April 28, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
17. Gabriellson J, Weiner D Pharmacokinetics and Pharmacodynamic Data Analysis: Concepts and Applications 2000, 141-147. Swedish Pharmaceutical Press, Stockholm, Sweden. 3rd ed.
18. Wang W, Ouyang SP The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics. J Pharmacokinet Biopharm 1998, 26:457-469.
19. Snedecor GW, Cochran WG Statistical Methods 1980, Iowa State University Press, Ames, Iowa.
20. Conover WJ Practical Nonparametric Statistics 1980, Wiley, New York, NY. 2nd ed.
21. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models 1996, SAS Institute Inc, Cary, NC.
22. Gupta SK, Okerholm RA, Eller M, et al. Comparison of the pharmacokinetics of two nicotine transdermal systems: Nicoderm and habitrol. J Clin Pharmacol 1995, 35:493-498.
23. Tønnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Eur Respir J. 1999, 13:238-246.
24. Shiffman S, Elash CA, Paton SM, et al. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 2000, 95:1185-1195.
25. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebocontrolled, double-blind study. Arch Intern Med. 1991, 151:749-752.
26. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations US Food and Drug Administration, Accessed April 28, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.